InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.083 0.001 (1.22%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$41 Update - Notification regarding unquoted securities - IMU 18 Jan 2024 9:49AM $0.105 $0.083 fallen by 20.95%
$41 Phase 1 CF33-hNIS Study Update - Positive Early Signals 17 Jan 2024 10:00AM $0.105 $0.083 fallen by 20.95%
$41 Notification regarding unquoted securities - IMU 17 Jan 2024 9:39AM $0.105 $0.083 fallen by 20.95%
$41 Imugene Presentation to JPMorgan Healthcare Conference 10 Jan 2024 10:58AM $0.120 $0.083 fallen by 30.83%
$41 Imugene and NeoImmuneTech to Improve Cancer Treatments 12 Dec 2023 9:28AM $0.093 $0.083 fallen by 10.75%
$41 Imugene to Present at Annual JPMorgan Healthcare Conference 11 Dec 2023 9:01AM $0.097 $0.083 fallen by 14.43%
$41 Application for quotation of securities - IMU 6 Dec 2023 6:32PM $0.092 $0.083 fallen by 9.78%
$41 New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS 6 Dec 2023 9:31AM $0.093 $0.083 fallen by 10.75%
$41 Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine 6 Dec 2023 8:50AM $0.093 $0.083 fallen by 10.75%
$41 Results of Meeting 30 Nov 2023 5:30PM $0.110 $0.083 fallen by 24.55%
$41 AGM Presentation 30 Nov 2023 2:03PM $0.118 $0.083 fallen by 29.36%
$41 FDA Fast Track Designation Granted for VAXINIA Trial Program 28 Nov 2023 8:53AM $0.091 $0.083 fallen by 8.79%
$41 Investor Webinar featuring COO, Dr Glover & CMO, Dr Woodard 14 Nov 2023 4:38PM $0.110 $0.083 fallen by 24.55%
$41 Azer-cel Hits Major Milestone in Phase 1b CAR T Trial 10 Nov 2023 9:03AM $0.110 $0.083 fallen by 24.55%
$41 Imugene Investor Webinar - MAST Study Update 7 Nov 2023 1:05PM $0.062 $0.083 risen by 33.87%
$41 Phase 1 CF33 VAXINIA Study Update - Positive Early Signals 6 Nov 2023 9:54AM $0.048 $0.083 risen by 72.92%
$41 Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study 2 Nov 2023 9:39AM $0.042 $0.083 risen by 97.62%
$41 Amended Annual Report 31 Oct 2023 6:19PM $0.043 $0.083 risen by 93.02%
$41 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2023 9:05AM $0.042 $0.083 risen by 97.62%
$41 Notice of Annual General Meeting/Proxy Form 30 Oct 2023 7:00PM $0.042 $0.083 risen by 97.62%
$41 Imugene Phase 1 onCARlytics CD19 virus clinical trial opens 26 Oct 2023 9:08AM $0.044 $0.083 risen by 88.64%
$41 Imugene B Cell & OV Platforms Featured at ESMO Congress 24 Oct 2023 9:44AM $0.041 $0.083 risen by 102.44%
$41 Change of Director's Interest Notice - PH 12 Oct 2023 6:01PM $0.047 $0.083 risen by 76.60%
$41 Change of Director's Interest Notice - LC 11 Oct 2023 7:39PM $0.050 $0.083 risen by 66%
$41 Change of Director's Interest Notice - PH 4 Oct 2023 7:25PM $0.044 $0.083 risen by 88.64%

251 - 275 of 1187 results

Page 11 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.